Blood Res.  2017 Sep;52(3):153-156. 10.5045/br.2017.52.3.153.

The role of cord blood banks in the cell therapy era: future perspectives

• Lee YH

• KMID: 2390974
• DOI: http://doi.org/10.5045/br.2017.52.3.153

Abstract

No abstract available.

MeSH Terms

Cell- and Tissue-Based Therapy*
Fetal Blood*

Figure

• 

  Fig. 1 Immunotherapeutic approaches to enhance the outcomes of CBT. The application of expansion techniques for CB-MNCs that operate by blocking in vitro differentiation of early progenitor cells could enhance engraftment potential. A fraction of cultured MSCs or Treg cells could then be used to prevent or treat GVHD. The generation of CAR-T/NK cells and expansion of T cells from fractions of CB could be applied to control relapsed patients after CBT. Abbreviations: CAR, chimeric antigen receptors; CBT, cord blood transplantation; GVHD, graft versus host disease; MNC, mononuclear cells; MSC, mesenchymal stem cell; NK, natural killer; Treg, regulatory T cell.

• 

  Fig. 2 Potential applicability of cord blood-derived cellullar resources in a variety settings. The TNC counts of CB banking guidelines need to be increased to enhance the utilization rate of stored CBs in public CBBs, and private and public CB samples with low cell doses can be used in clinical trials in transplant settings as well as non-transplant settings. The cGMP cell factories could manipulate fractionated CBs and generate cellular products that could be utilized for cell therapies. Abbreviations: BPD, bronchopulmonary dysplasia; CAR, chimeric antigen receptors; CBB, cord blood bank; cGMP, current good manufacturing practice; CMP, cardiomyopathy; DC, dendrtitic cell; DLI, donor lymphocyte infusion; DM, diabetes mellitus; GVHD, graft versus host disease; HIE, hypoxic ischemic encephalopathy; HSC, hematopoietic stem cell; iPS, induced pluripotent stem cell; MSC, mesenchymal stem cell; NK, natural killer cell; TNC, total nucleated cell; Treg, regulatory T cell.

Reference

1. Lee YH, Kwon YH, Hwang K, et al. Analysis of stored and transplanted cord blood units from KoreaCORD: reappraisal of banking guidelines and selection strategy. Transfusion. 2013; 53:123–127.

2. Ballen KK, Verter F, Kurtzberg J. Umbilical cord blood donation: public or private. Bone Marrow Transplant. 2015; 50:1271–1278.

3. Lee YH, Choi KV, Moon JH, et al. Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy. J Transl Med. 2012; 10:58.

4. Berglund S, Gertow J, Uhlin M, Mattsson J. Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation. Cytotherapy. 2014; 16:1528–1536.

5. Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y. Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PLoS One. 2015; 10:e0136991.

6. Brunstein CG, Miller JS, McKenna DH, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2016; 127:1044–1051.

7. McKenna DH Jr, Sumstad D, Kadidlo DM, et al. Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy. 2017; 19:250–262.

8. Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol. 2014; 153:23–30.

9. Mehta RS, Shpall EJ, Rezvani K. Cord Blood as a Source of Natural Killer Cells. Front Med (Lausanne). 2016; 2:93.

10. Kayserova J, Vcelakova J, Stechova K, et al. Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clin Immunol. 2014; 153:49–55.